Connect with us


Grow Pharma apologises for price rises, blaming ‘escalating costs’

The company’s flower-based cannabis products have increased in price by 50p per gram.



Grow Pharma apologises for price rises, blaming ‘escalating costs’

Grow Pharma has apologised to patients after increasing the costs of its cannabis flower products due to rising bills.

The boss of Grow Pharma, one of the UK’s major cannabis producers, says he is ‘truly sorry’ for price increases, which came into force on 1 October.

Staff at the private cannabis clinic Integro Clinics – one of Grow Pharma’s industry partners – informed patients that the costs of the company’s own range of flower-based products had increased by 50p per gram.

The company has blamed the current economic climate, citing soaring energy bills, ‘escalating’ transportation costs and the poor exchange rate as reasons behind the decision. 

According to the firm’s website, Grow Pharma supplies cannabis-based medicines to over 2,000 patients every month across the UK. 

In May it announced a new range of ‘low-priced products’, cultivated by licensed producer PHCANN in North Macedonia.

Speaking to Cannabis Health, Grow Pharma’s CEO, Pierre van Weperen, said: “We are truly sorry about having to do this.

“As you can imagine, growing cannabis indoors requires significant amounts of energy and our energy bills have gone through the roof. 

“On top of that, transportation costs have escalated, and the exchange rate versus the euro adds another five per cent to the increase.”

Earlier this year, the firm launched the Grow Access Project (GAP), in collaboration with Integro Clinics, in a bid to improve patient access to cannabis by reducing cost-barriers. 

The scheme offered 500 free consultations to patients, as well as reducing other clinic costs for patients on means-tested benefits and for veterans of the UK Armed Forces.

Van Weperen continued: “We have looked at finding other ways to manage this. Integro, for example, has lowered consultation fees on top of the 500 free consultations they offered for GAP patients, and the repeat prescription cost is now only £10.” 

He also commented on the lack of communication around the price increase with patients who may be affected, saying that any public messaging could risk a breach of strict MHRA guidelines around the advertising of unlicensed medicines. 

“Communicating price changes to patients is a compliance nightmare,” he added.

“We cannot send out messages announcing anything since it would be seen as a promotion of medicines to the public, which has severe penalties for us.”

Along with its pharmacy partner IPS, Grow Pharma imports and distributes medicines produced by major brands, including Aurora, Tilray, Spectrum and Columbia Care. These will not be affected by the price increase.


Home » Industry » Grow Pharma apologises for price rises, blaming ‘escalating costs’

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister titles, Cannabis Wealth and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.